TransCode Therapeutics Inc. (RNAZ) announced publication in Cancer Nanotechnology of preclinical data supporting therapeutic potential of TTX-MC138(MN-anti-miR10b) in metastatic breast cancer.
In Thursday pre-market trade, RNAZ was trading at $3.09 up $0.47 or 17.94%.
The study confirmed the biodistribution of TTX-MC138 in models of metastatic cancer, supporting TransCode's TTX platform for delivery of RNA targeted therapy to metastatic solid tumors.
The company looks forward to its Phase 0 study which has the potential to establish clinical proof-of-concept for this therapy.
TransCode expects to file an exploratory investigational new drug (eIND) application for TTX-MC138 in the first quarter of 2022 to support a Phase 0 study in patients with metastatic cancer.
Under an eIND, FDA approval may be obtained more quickly and at lower cost than with a traditional IND for therapeutic agents.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.